These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34572273)

  • 1. Immunity and Breast Cancer: Focus on Eosinophils.
    Poncin A; Onesti CE; Josse C; Boulet D; Thiry J; Bours V; Jerusalem G
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment.
    Onesti CE; Josse C; Poncin A; Frères P; Poulet C; Bours V; Jerusalem G
    Oncotarget; 2018 Sep; 9(72):33719-33733. PubMed ID: 30263098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
    Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
    Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophils in Cancer: Favourable or Unfavourable?
    Sakkal S; Miller S; Apostolopoulos V; Nurgali K
    Curr Med Chem; 2016; 23(7):650-66. PubMed ID: 26785997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Insights Into the Role of Tissue Eosinophils in the Progression of Colorectal Cancer: A Literature Review.
    Saraiva AL; Carneiro F
    Acta Med Port; 2018 Jun; 31(6):329-337. PubMed ID: 30020878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
    Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
    Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S
    Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
    Stovgaard ES; Nielsen D; Hogdall E; Balslev E
    Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer.
    Iwasaki K; Torisu M; Fujimura T
    Cancer; 1986 Sep; 58(6):1321-7. PubMed ID: 3742457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer.
    Baba M; Takahashi M; Yamashiro K; Yokoo H; Fukai M; Sato M; Hosoda M; Kamiyama T; Taketomi A; Yamashita H
    Surg Today; 2016 Jul; 46(7):843-51. PubMed ID: 26494004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between interleukin-5 production and variations in eosinophil counts during HIV infection in West Africa: influence of Mycobacterium tuberculosis infection.
    Diagbouga S; Aldebert D; Fumoux F; Capron M; Ledru E
    Scand J Immunol; 1999 Feb; 49(2):203-9. PubMed ID: 10075026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.
    Lusho S; Durando X; Bidet Y; Molnar I; Kossai M; Bernadach M; Lacrampe N; Veyssiere H; Cavaille M; Gay-Bellile M; Radosevic-Robin N; Abrial C
    Medicine (Baltimore); 2020 Dec; 99(50):e23418. PubMed ID: 33327268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophils in the Tumor Microenvironment.
    Mattei F; Andreone S; Marone G; Gambardella AR; Loffredo S; Varricchi G; Schiavoni G
    Adv Exp Med Biol; 2020; 1273():1-28. PubMed ID: 33119873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.